|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's Range||63.30 - 65.19|
|52 Week Range||60.14 - 82.15|
|Beta (3Y Monthly)||1.26|
|PE Ratio (TTM)||21.12|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||2.00 (2.86%)|
|1y Target Est||88.57|
Shares of the drug store plummeting after reporting lower-than-expected results and a disappointing 2019 outlook. This comes after closing a $70 billion dollar acquisition of Aetna in November. Yahoo Finance's Seana Smith joins Jackie DeAngelis with her take.
U.S. stocks ended in the green as investors digested minutes detailing the deliberations from the Federal Open Market Committee’s latest meeting.
BEIJING (AP) — Asian stock markets were little-changed Thursday following a listless day on Wall Street ahead of U.S.-Chinese negotiations aimed at ending a tariff battle.
The Woonsocket, R.I.-based company, which in November completed its nearly $70 billion acquisition of insurer Aetna Inc., said that it was taking rapid steps to address the problems, including a cost-cutting effort, and that its ambitious deal positioned it for long-term growth. For 2019, the company said it was projecting adjusted earnings per share of $6.68 to $6.88, compared with analysts’ estimates of $7.41 a share, as polled by Refinitiv. CVS said its results are being hurt by factors including smaller benefits from the rollout of new generic drugs and the performance of Omnicare, its long-term-care pharmacy business.
U.S. stocks closed near the break-even line on Wednesday after the Federal Reserve released the minutes for its January meeting in the afternoon. The minutes were largely consistent with recent public comments made by Federal Open Market Committee members. Markets closed flat as the Fed minutes came largely as expected.
shares closed 8.1% lower Wednesday at $64.22, after it posted stronger-than-expected fourth-quarter earnings but issued 2019 profit guidance that fell far short of Wall Street forecasts linked to "significant additional deterioration" in its long-term care business. CVS Health said adjusted earnings for the three months ending in December came in at $2.14 per share, up 11.5% from the same period last year and firmly ahead of the Street consensus of $2.05 per share. Looking into 2019, CVS said it sees cash flow from operations in the range of $9.8 billion to $10.3 billion and full-year GAAP earnings of between $4.88 and $5.08 per share, or $6.68 to $6.88 on an adjusted basis, well below the Refinitiv forecast of $7.41 per share and the 2018 tally of $7.08 per share.
NEW YORK, NY / ACCESSWIRE / February 20, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVS Health Corporation("CVS" or the "Company") ...
The Dow Jones Industrial Average finished higher Wednesday following the release of minutes from the January meeting of the Federal Reserve's rate-setting committee. posted stronger-than-expected fourth-quarter earnings but its 2019 profit guidance fell far short of Wall Street forecasts. said it was replacing its general counsel Dane Butswinkas just two months after he joined the electric carmaker.
"After the payment of our shareholder dividend, capital retention to support our insurance operation and growth capital expenditures of $2.3 billion to $2.6 billion, we will use the remaining cash available to continue to pay down debt," CFO Eva Boratto told analysts. It's no secret that this is largely due to the blockbuster $68 billion deal for major insurer Aetna. The drag of debt payments on this acquisition is a big question mark for 2019 as the insurer seeks integration into the broader CVS brand.